Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ligand Pharmaceuticals Incorporated's Business Segments
Ligand Pharmaceuticals Incorporated's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Development and Licensing of Biopharmaceutical Assets
Total Revenue
$ 64
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Development and Licensing of Biopharmaceutical Assets100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Development and Licensing of Biopharmaceutical Assets | $ 64 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Royalty75.4%
- Intangible Royalty Assets58.7%
- Filspari21.3%
- Financial Royalty Assets16.8%
- Material Sales, Captisol12.5%
- Contract revenue and other income12.1%
- Contract revenue and income12.1%
- Kyprolis11.1%
- Qarziba9.7%
- Contract and Revenue Income, Other7.9%
- Royalty Intangible, Other6.7%
- Intangible Ohtuvayre6.5%
- Financial Ohtuvayre Inventors5.2%
- Rylaze5%
- Contract revenue4.2%
- Capvaxive3.6%
- Teriparatide injection2.3%
- Vaxneuvance2.1%
- Financial Royalty, Other1.9%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 48 | 75.4% |
| Intangible Royalty Assets | $ 37 | 58.7% |
| Filspari | $ 14 | 21.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
16 more categories available
Sign in to unlock the full Ligand Pharmaceuticals Incorporated dataset.
Description of Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that was founded in 1987 and is based in San Diego, California. The company's primary focus is on developing innovative medicines to treat serious diseases, and it has a diversified portfolio of drugs in various stages of development.
Ligand's primary area of expertise is in developing small molecule drugs that can selectively target specific cellular pathways to treat diseases. The company's technology platform is based on its proprietary Captisol® technology, which is a drug delivery technology that improves the solubility and bioavailability of drugs. This technology has been licensed to various pharmaceutical companies for the development of their own drugs.
The company has a broad portfolio of drugs that are either in clinical trials or have been approved by regulatory agencies. Ligand's current portfolio includes drugs for the treatment of cancer, inflammatory diseases, metabolic disorders, and other diseases. Some of the drugs in the company's portfolio include Promacta® (eltrombopag), Amgen's Omecamtiv Mecarbil (a cardiac muscle activator), and Evomela® (melphalan hydrochloride), among others.
Ligand has a business model that involves licensing its technology and intellectual property to pharmaceutical companies for the development of their own drugs. This allows the company to generate royalties and other revenue streams from these partnerships. It also allows the company to diversify its pipeline and reduce its reliance on any individual drug or therapeutic area.
The company has received numerous awards and recognitions for its innovative technology and drug development programs. In 2020, Ligand was named to Forbes America's Best Small Companies list, and its Captisol® technology was named one of R&D Magazine's 100 most significant innovations of the year.
Overall, Ligand Pharmaceuticals Inc. is a leading biopharmaceutical company that is focused on developing innovative drugs to treat serious diseases. The company's technology platform and diversified pipeline make it a strong candidate for continued growth and success in the biotech industry.
Ligand's primary area of expertise is in developing small molecule drugs that can selectively target specific cellular pathways to treat diseases. The company's technology platform is based on its proprietary Captisol® technology, which is a drug delivery technology that improves the solubility and bioavailability of drugs. This technology has been licensed to various pharmaceutical companies for the development of their own drugs.
The company has a broad portfolio of drugs that are either in clinical trials or have been approved by regulatory agencies. Ligand's current portfolio includes drugs for the treatment of cancer, inflammatory diseases, metabolic disorders, and other diseases. Some of the drugs in the company's portfolio include Promacta® (eltrombopag), Amgen's Omecamtiv Mecarbil (a cardiac muscle activator), and Evomela® (melphalan hydrochloride), among others.
Ligand has a business model that involves licensing its technology and intellectual property to pharmaceutical companies for the development of their own drugs. This allows the company to generate royalties and other revenue streams from these partnerships. It also allows the company to diversify its pipeline and reduce its reliance on any individual drug or therapeutic area.
The company has received numerous awards and recognitions for its innovative technology and drug development programs. In 2020, Ligand was named to Forbes America's Best Small Companies list, and its Captisol® technology was named one of R&D Magazine's 100 most significant innovations of the year.
Overall, Ligand Pharmaceuticals Inc. is a leading biopharmaceutical company that is focused on developing innovative drugs to treat serious diseases. The company's technology platform and diversified pipeline make it a strong candidate for continued growth and success in the biotech industry.
Ligand Pharmaceuticals Incorporated is a dynamic biopharmaceutical company that specializes in advancing the development and commercialization of innovative small molecule drugs and therapeutic modalities. The company is structured around three primary segments: Captisol, OmniAb, and Partnered Programs. Each segment harbors unique technologies, products, and services tailored to meet various medical needs and support pharmaceutical partners in their drug development endeavors.
1. Captisol Segment:
The Captisol segment is known for its proprietary technology that facilitates the formulation of drug compounds that have poor solubility or stability. Captisol, a modified cyclodextrin, provides significant advantages in enhancing the solubility, bioavailability, and stability of these challenging drug candidates.
Products and Services:
- Captisol-Enabled Products: Ligand has developed and commercialized several drugs enabled by Captisol technology, including:
- Kyprolis (carfilzomib): An FDA-approved treatment for multiple myeloma, which leverages the Captisol formulation for improved solubility and efficacy.
- Nexterone (amiodarone): An anti-arrhythmic medication utilized for managing life-threatening ventricular arrhythmias, also benefiting from Captisols solubilization properties.
- Captisol Licensing: Ligand provides licensing opportunities for pharmaceutical and biotechnology companies to access Captisol technology, allowing partners to integrate this innovative formulation approach into their drug formulations during development.
- Captisol Sales: The company engages in selling Captisol directly to its partners, enabling them to enhance their therapeutic candidates with the benefits of its proprietary solubilization technology.
OmniAb Segment:
The OmniAb segment is a suite of advanced therapeutic antibody development platforms. It incorporates technologies like OmniRat, OmniMouse, OmniFlic, and OmniChicken, which are capable of generating fully human antibodies with optimized attributes, such as high affinity and specificity.
Products and Services:
- OmniAb Platform: Ligand provides a comprehensive toolkit for creating fully human monoclonal antibodies, which are essential for therapeutic and diagnostic applications, targeting a broad range of disease-relevant antigens.
- Collaborations: Ligand has formed strategic collaborations, such as the one with Vernalis, to leverage OmniRat technology in the discovery of novel drug candidates, which underscores the versatility and application of the OmniAb technology in developing new therapeutics.
- Licensing: Similar to the Captisol segment, Ligand offers licensing opportunities for the OmniAb technology, allowing other pharmaceutical and biotechnology firms access to these innovative platforms for the discovery and development of antibody-based therapies.
Partnered Programs Segment:
Ligands Partnered Programs segment emphasizes collaborative development opportunities with other biotechnology and pharmaceutical companies. This segment allows for extensive research and development, complemented by support in manufacturing and commercialization.
Products and Services:
- Development Partnerships: Ligand has established numerous development partnerships with leading pharmaceutical companies, focusing on bringing innovative drug candidates to market across various therapeutic indications.
- Licensing: The company licenses its patented technologies and product candidates to partners, facilitating their development and commercialization efforts, which can lead to market-ready therapeutic solutions.
- Manufacturing and Supply: Ligand provides essential manufacturing and supply services, ensuring that its partners have the necessary infrastructure and resources for the successful commercialization of their products.
Conclusion:
Ligand Pharmaceuticals Inc. exhibits a robust and multifaceted approach to drug development through its main segments: Captisol, OmniAb, and Partnered Programs. Each segment not only contributes to the companys capabilities in formulating and optimizing drug candidates but also establishes strong partnerships within the biopharmaceutical sphere, highlighting Ligands role as an enabler of innovative therapeutic solutions across various healthcare sectors. By leveraging its proprietary technologies and a collaborative model, Ligand continues to advance the frontiers of pharmaceutical development and contributes to addressing pressing medical needs.
1. Captisol Segment:
The Captisol segment is known for its proprietary technology that facilitates the formulation of drug compounds that have poor solubility or stability. Captisol, a modified cyclodextrin, provides significant advantages in enhancing the solubility, bioavailability, and stability of these challenging drug candidates.
Products and Services:
- Captisol-Enabled Products: Ligand has developed and commercialized several drugs enabled by Captisol technology, including:
- Kyprolis (carfilzomib): An FDA-approved treatment for multiple myeloma, which leverages the Captisol formulation for improved solubility and efficacy.
- Nexterone (amiodarone): An anti-arrhythmic medication utilized for managing life-threatening ventricular arrhythmias, also benefiting from Captisols solubilization properties.
- Captisol Licensing: Ligand provides licensing opportunities for pharmaceutical and biotechnology companies to access Captisol technology, allowing partners to integrate this innovative formulation approach into their drug formulations during development.
- Captisol Sales: The company engages in selling Captisol directly to its partners, enabling them to enhance their therapeutic candidates with the benefits of its proprietary solubilization technology.
OmniAb Segment:
The OmniAb segment is a suite of advanced therapeutic antibody development platforms. It incorporates technologies like OmniRat, OmniMouse, OmniFlic, and OmniChicken, which are capable of generating fully human antibodies with optimized attributes, such as high affinity and specificity.
Products and Services:
- OmniAb Platform: Ligand provides a comprehensive toolkit for creating fully human monoclonal antibodies, which are essential for therapeutic and diagnostic applications, targeting a broad range of disease-relevant antigens.
- Collaborations: Ligand has formed strategic collaborations, such as the one with Vernalis, to leverage OmniRat technology in the discovery of novel drug candidates, which underscores the versatility and application of the OmniAb technology in developing new therapeutics.
- Licensing: Similar to the Captisol segment, Ligand offers licensing opportunities for the OmniAb technology, allowing other pharmaceutical and biotechnology firms access to these innovative platforms for the discovery and development of antibody-based therapies.
Partnered Programs Segment:
Ligands Partnered Programs segment emphasizes collaborative development opportunities with other biotechnology and pharmaceutical companies. This segment allows for extensive research and development, complemented by support in manufacturing and commercialization.
Products and Services:
- Development Partnerships: Ligand has established numerous development partnerships with leading pharmaceutical companies, focusing on bringing innovative drug candidates to market across various therapeutic indications.
- Licensing: The company licenses its patented technologies and product candidates to partners, facilitating their development and commercialization efforts, which can lead to market-ready therapeutic solutions.
- Manufacturing and Supply: Ligand provides essential manufacturing and supply services, ensuring that its partners have the necessary infrastructure and resources for the successful commercialization of their products.
Conclusion:
Ligand Pharmaceuticals Inc. exhibits a robust and multifaceted approach to drug development through its main segments: Captisol, OmniAb, and Partnered Programs. Each segment not only contributes to the companys capabilities in formulating and optimizing drug candidates but also establishes strong partnerships within the biopharmaceutical sphere, highlighting Ligands role as an enabler of innovative therapeutic solutions across various healthcare sectors. By leveraging its proprietary technologies and a collaborative model, Ligand continues to advance the frontiers of pharmaceutical development and contributes to addressing pressing medical needs.